Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Change in Cash: 2020-2025

Historic Change in Cash for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $109.1 million.

  • Apellis Pharmaceuticals' Change in Cash rose 196.47% to $109.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.4 million, marking a year-over-year increase of 249.04%. This contributed to the annual value of $60.3 million for FY2024, which is 130.04% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Change in Cash of $109.1 million as of Q3 2025, which was up 837.67% from $11.6 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Change in Cash ranged from a high of $356.4 million in Q4 2021 and a low of -$300.1 million during Q1 2021.
  • Its 3-year average for Change in Cash is -$6.6 million, with a median of $11.6 million in 2025.
  • Data for Apellis Pharmaceuticals' Change in Cash shows a peak YoY increase of 3,263.97% (in 2023) and a maximum YoY decrease of 706.84% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Apellis Pharmaceuticals' Change in Cash stood at $356.4 million in 2021, then slumped by 109.08% to -$32.4 million in 2022, then crashed by 212.60% to -$101.2 million in 2023, then soared by 114.20% to $14.4 million in 2024, then skyrocketed by 196.47% to $109.1 million in 2025.
  • Its Change in Cash stands at $109.1 million for Q3 2025, versus $11.6 million for Q2 2025 and -$52.8 million for Q1 2025.